CO-EXPRESSION OF RECOMBINANT IMMUNE-CHECKPOINT RECEPTOR AND IMMUNE-CHECKPOINT INHIBITOR AND APPLICATION

Title:

CO-EXPRESSION OF RECOMBINANT IMMUNE-CHECKPOINT RECEPTOR AND IMMUNE-CHECKPOINT INHIBITOR AND APPLICATION

Document Type and Number:

WIPO Patent Application WO/2018/006880

Kind Code:

A1

Abstract:

A transgenic lymphocyte, a construct, and a therapeutic composition for treating cancer. The transgenic lymphocyte has a silenced cellular immune-checkpoint and expresses a recombinant receptor. The recombinant receptor comprises: a cellular immune-checkpoint molecular segment; an immune stimulator molecular segment; and a T-cell receptor zeta chain.

More Like This:

WO/2000/075332	USE OF THE REGULATORY SUBUNIT OF THE CAMP DEPENDENT PROTEIN KINASE (PKA) FROM DICTYOSTELIUM FOR cAMP MEASUREMENTS
WO/2023/280144	FUSION PROTEIN AND MEDICAL USE THEREOF
JPH0776240	INDUSTRIAL APPLICABILITY Monochrome-nal antibody reactive with endotoxin core.

Inventors:

CHEN SIYI (CN)

Application Number:

PCT/CN2017/092376

Publication Date:

January 11, 2018

Filing Date:

July 10, 2017

Export Citation:

Click for automatic bibliography generation Help

Assignee:

LIFESEQ LTD CORPORATION (CN)

International Classes:

C07K19/00; A61K35/17; A61P35/00; C12N5/10; C12N7/01; C12N15/62

Domestic Patent References:

WO2016025880A1	2016-02-18
WO2016070061A1	2016-05-06
WO2016014565A2	2016-01-28

Foreign References:

CN105392888A	2016-03-09
CN103965361A	2014-08-06
CN104769103A	2015-07-08

Attorney, Agent or Firm:

TSINGYIHUA INTELLECTUAL PROPERTY LLC (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: ANISOTROPIC MAGNETIC RESISTANCE AND CURRENT SENSOR WITHOUT SETTING AND RESETTING APPARATUS

Next Patent: RECOMBINANT IMMUNE-CHECKPOINT RECEPTOR AND APPLICATION THEREOF